Literature DB >> 22624710

Opening a new GATAway for treating KRAS-driven lung tumors.

Mariano Barbacid1.   

Abstract

In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations unveil new armamentaria to fight this deadly disease.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Year:  2012        PMID： 22624710      PMCID： PMC4854325          DOI： 10.1016/j.ccr.2012.04.032

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma.

Authors:  Rafael B Blasco; Sarah Francoz; David Santamaría; Marta Cañamero; Pierre Dubus; Jean Charron; Manuela Baccarini; Mariano Barbacid
Journal:  Cancer Cell       Date:  2011-04-21       Impact factor: 31.743

2.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

Review 3.  Non-germline genetically engineered mouse models for translational cancer research.

Authors:  Joerg Heyer; Lawrence N Kwong; Scott W Lowe; Lynda Chin
Journal:  Nat Rev Cancer       Date:  2010-07       Impact factor: 60.716

4.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Authors:  Marta Puyol; Alberto Martín; Pierre Dubus; Francisca Mulero; Pilar Pizcueta; Gulfaraz Khan; Carmen Guerra; David Santamaría; Mariano Barbacid
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

5.  A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

Authors:  Ji Luo; Michael J Emanuele; Danan Li; Chad J Creighton; Michael R Schlabach; Thomas F Westbrook; Kwok-Kin Wong; Stephen J Elledge
Journal:  Cell       Date:  2009-05-29       Impact factor: 41.582

6.  Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma.

Authors:  Etienne Meylan; Alison L Dooley; David M Feldser; Lynn Shen; Erin Turk; Chensi Ouyang; Tyler Jacks
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

7.  Reduced cell proliferation by IKK2 depletion in a mouse lung-cancer model.

Authors:  Yifeng Xia; Narayana Yeddula; Mathias Leblanc; Eugene Ke; Yonghui Zhang; Eric Oldfield; Reuben J Shaw; Inder M Verma
Journal:  Nat Cell Biol       Date:  2012-02-12       Impact factor: 28.824

8.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

9.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440
  9 in total
  4 in total

Review 1.  KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.

Authors:  Javier de Castro Carpeño; Cristóbal Belda-Iniesta
Journal:  Transl Lung Cancer Res       Date:  2013-04

2.  Neferine, a novel ROCK1-targeting inhibitor, blocks EMT process and induces apoptosis in non-small cell lung cancer.

Authors:  Po Hu; Peng Wan; Anna Xu; Binghui Yan; Chunmei Liu; Qixuan Xu; Zhenhuan Wei; Jingyi Xu; Siqi Liu; Guangming Yang; Yang Pan
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-19       Impact factor: 4.322

3.  GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.

Authors:  Mathewos Tessema; Christin M Yingling; Amanda M Snider; Kieu Do; Daniel E Juri; Maria A Picchi; Xiequn Zhang; Yushi Liu; Shuguang Leng; Carmen S Tellez; Steven A Belinsky
Journal:  J Thorac Oncol       Date:  2014-06       Impact factor: 15.609

Review 4.  Mouse models for lung cancer.

Authors:  Min-chul Kwon; Anton Berns
Journal:  Mol Oncol       Date:  2013-02-19       Impact factor: 6.603
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.